Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

Bullboard (TSXV:XRTX)

View:
Post by Stockwonderon Oct 09, 2024 7:12am

V.XRTX XORTX Initiates Precision Medicine Program

Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism Click here to read NEWS
Post by whytestockson Sep 03, 2024 1:00pm

Independent Proxy Advisory Firm ISS Recommends XORTX Shareho

Breaking News: $XRTX Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of ShareholdersCALGARY, Alberta, Sept. 03, ...more  
Post by StockHawk1on Mar 20, 2024 6:53pm

XRTX.v Unveils 2023 Milestones and 2024 Objectives

Yesterday, the pharmaceutical company XORTX Therapeutics Inc. (XRTX.v XRTX) shared its progress in 2023 and goals for 2024, mainly concerning its lead program aimed at treating a kidney disease called ...more  
Post by Betteryear2on Mar 19, 2024 10:07pm

XORTX Highlights Achievements of 2023

CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical ...more  
Post by KOkidneydiseaseon Mar 19, 2024 1:12pm

use Bluestar BioAdvisors est. net sales to calc a CF NPV

XRx-008 Program Highlights – Independent Commercial Assessment In support of ongoing pharmaceutical partnership discussions, XORTX initiated an independent commercial assessment of the XRx-008 ...more  
Post by waves1on Mar 15, 2024 4:58pm

New Patent for Treatment of Chronic Kidney Disease Submitted

Xorlo program which is in a Phase 2/3 trial in patients with stage 2-4 ADPKD.   XRTX is continuing to scale up its supply and to conduct pre-launch activities in prep for a ...more  
Post by StockHawk1on Mar 12, 2024 7:53pm

Health Tech: Breakthroughs in Polycystic Kidney Disease and

With a primary focus on polycystic kidney disease and diabetic kidney disease, XORTX Therapeutics (XRTX.v XRTX) is advancing clinical trials for potential groundbreaking therapies that could ...more  
Post by waves1on Mar 08, 2024 5:30pm

$14/share Price Target from Alliance Global Partners

New on my Radar: XORTX Therapeutics (NASDAQ/TSXV: XRTX) - $14/share Price Target from Alliance Global Partners   In developing Innovative therapies to improve the quality of life of patients ...more  
Post by Iseneschalon Mar 07, 2024 10:26am

XRTX ....Halted on NASDAQ (LUDP) seriously !!!!

No volume (as usual) .....and minimal Price Action Whi in the fack calls the shots ???? Unreal !
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities